WHWKHIGH SIGNALFINANCIAL10-K

WHWK experienced a substantial decline in revenue while R&D expenses grew meaningfully, indicating a strategic pivot toward increased drug development investment despite reduced commercial performance.

The company has successfully advanced two drug candidates (HWK-007 and HWK-016) through FDA IND clearance with Phase 1 trials now recruiting, representing significant regulatory progress. However, the dramatic revenue contraction combined with substantially higher R&D spending creates increased cash burn risk, though the company appears to be prioritizing pipeline advancement over near-term profitability.

Comparing 2026-03-12 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company in transition, with revenue declining substantially while R&D expenses grew meaningfully to $91M, reflecting heightened investment in drug development. Operating cash outflows increased significantly to $97.4M, though this was partially offset by improved net income due to non-operating factors. Despite the increased cash burn, the company maintained a solid cash position of $37.6M and reduced total liabilities, suggesting adequate liquidity to fund ongoing clinical operations in the near term.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+78.3%
$51.0M→$91.0M

R&D investment increased 78.3% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
-72.5%
$26.0M→$7.1M

Revenue declined 72.5% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
-69.6%
-$67.5M→-$114.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
+67.7%
-$63.7M→-$20.6M

Net income grew 67.7% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
-66.6%
$1.7M→$552K

Capex reduced 66.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-63.6%
-$59.5M→-$97.4M

Operating cash flow fell 63.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+31%
$28.7M→$37.6M

Cash position surged 31% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
-18.8%
$36.7M→$29.8M

SG&A reduced 18.8% — improved cost efficiency or headcount reduction improving operating margins.

Total Liabilities
Balance Sheet
-18.6%
$17.8M→$14.5M

Liabilities reduced 18.6% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-15%
$17.1M→$14.5M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-28
ADDED
In December 2024, we entered into an intellectual property license agreement (the WuXi License Agreement ) with WuXi Biologics (Shanghai FX) Co., Ltd.
The antibody targeting SEZ6 is a biparatopic SEZ6 ( biSEZ6 ) antibody targeting two different epitopes on SEZ6.
We submitted investigational new drug ( IND ) applications with the U.S.
Food and Drug Administration ( FDA ) for HWK-007 for the treatment of solid tumors, including non-small cell lung cancer ( NSCLC ) and ovarian cancer, and HWK-016 for the treatment of ovarian and endrometrial cancers, in the fourth quarter of 2025; and we anticipate submitting an IND for HWK-206 for the treatment of small cell lung cancer ("SCLC") and neuroendocrine tumors ( NETs ) in mid-2026.
The FDA has cleared the IND applications for HWK-007 and HWK-016 and the Phase 1 trials for each asset are now actively recruiting.
We expect data readouts in the first half of 2027 from each trial.
Under the Divestiture Agreement, KAKEN acquired 100% of the outstanding shares of capital stock of Aadi Subsidiary from us at the closing of the transaction for a cash payment of $102.4 million (following applicable purchase price adjustments under the Divestiture Agreement) (the "FYARRO Divestiture").
The principal components of our strategy include: We leverage an optimized, next-generation ADC architecture.
These next-generation ADC architectures are typified by improved linker-antibody stability, optimized pharmacokinetics and improved inhibitor payloads, such as using a TOP1 inhibitor in lieu of monomethyl auristatin E ( MMAE ).
Our ADC Therapies are designed to leverage an optimized, next-generation ADC architecture engineered for selective tumor delivery, modality-leading stability and optimized TOP1 inhibition for maximal tumor killing while minimizing potential toxicity.
REMOVED
We recently entered into an intellectual property license agreement (the WuXi License Agreement ) with WuXi Biologics (Shanghai FX) Co., Ltd.
The antibody targeting SEZ6 is a biparatopic SEZ6 ("biSEZ6") antibody targeting two different epitopes on SEZ6.
We anticipate submitting three investigational new drug ( IND ) applications with the U.S.
Food and Drug Administration ( FDA ) in the coming 12 to 24 months, starting with HWK-007 for the treatment of solid tumors, including non-small cell lung cancer ( NSCLC ) and ovarian cancer, in the second half of 2025; HWK-016 for the treatment of cancers of female origin by the end of 2025; and HWK-206 for the treatment of cancers of neuroendocrine origin in mid-2026.
On February 22, 2022, we launched FYARRO in the United States for treatment of advanced malignant PEComa and recognized net product sales of $26.0 million and $24.4 million for the years ended December 31, 2024 and 2023, respectively.
The principal components of our strategy include: We leverage next wave ADC architecture.
Next wave ADC architectures are typified by improved linker-antibody stability, optimized pharmacokinetics and improved inhibitor payloads, such as using TOPO1 inhibitor in lieu of monomethyl auristatin E ( MMAE ).
We look to continue to build our portfolio through strategic partnerships.
Importantly, we prioritized the ability to be in the clinic quickly, and we expect to file INDs in the next 12 to 24 months, starting with our PTK7-directed asset in the second half of 2025, followed closely by the MUC16-directed asset by the end of 2025, and the SEZ6-directed asset in mid-2026.
HWK-007 presents a differentiated opportunity to be among the first next wave ADCs in clinical development for high PTK7 expressing cancers, including NSCLC, ovarian cancer, and several other major indications.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →